drugset / Trial / NCT05303376
Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a Phase 1 and phase 2, adaptive, placebo-controlled, double-blind, randomized single-dose study in participants with Severe COVID-19 illness.
Timeline
- Start
- 2022-02-22
- Primary completion
- 2023-06-27
- Completion
- 2023-06-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBIO123 | Monoclonal antibody | 5 mg | Inhaled |
| Subject | IBIO123 | Monoclonal antibody | 10 mg | Inhaled |